Date published: 2025-10-10

021-6093-6350

SCBT Portrait Logo
Seach Input

C21orf77 抑制因子

Chemical inhibitors of C20orf77 function through various biochemical mechanisms to inhibit the protein's activity. Staurosporine, a well-known protein kinase inhibitor, disrupts the phosphorylation events that are critical for the activity of many proteins, including C20orf77. By inhibiting these kinases, Staurosporine can prevent the phosphorylation that C20orf77 might require for its function. Similarly, Wortmannin and LY294002, both phosphoinositide 3-kinases (PI3K) inhibitors, disrupt signaling pathways that C20orf77 relies upon. By inhibiting PI3K, these chemicals can prevent the activation of downstream targets that may be essential for the function of C20orf77. Rapamycin, by inhibiting the mammalian target of rapamycin (mTOR), can also disrupt downstream signaling pathways associated with C20orf77, potentially inhibiting its function. This is similar to the action of U0126 and PD98059, which selectively inhibit MEK1/2 and MEK respectively, thereby preventing the activation of the ERK pathway, a pathway that C20orf77 may depend on for its activity.

Furthermore, SB203580 targets p38 MAP Kinase, which is involved in response to stress and cytokines. Inhibition of p38 MAPK by SB203580 can interrupt signaling cascades that C20orf77 is part of, leading to its inhibition. SP600125, a JNK inhibitor, can halt signaling processes that are essential for C20orf77's activity. Triciribine aims at AKT inhibition, which prevents the phosphorylation and activation of proteins that are in the same pathway as C20orf77, thus leading to its functional inhibition. Dasatinib, a broad-spectrum tyrosine kinase inhibitor, can suppress the activity of kinases that regulate the activity of proteins such as C20orf77. Leflunomide inhibits dihydroorotate dehydrogenase, which can reduce the synthesis of proteins that are part of C20orf77's pathway, resulting in functional inhibition. Lastly, Bortezomib, as a proteasome inhibitor, causes the accumulation of misfolded proteins, disrupting cellular homeostasis and potentially inhibiting the function of C20orf77 through stress-induced pathways. Each chemical operates by disrupting specific pathways or cellular processes that are crucial for the proper functioning of C20orf77, thereby achieving inhibition.

関連項目

Items 1 to 10 of 12 total

展示:

产品名称CAS #产品编号数量价格应用排名

Palbociclib

571190-30-2sc-507366
50 mg
¥3554.00
(0)

抑制参与细胞周期进展的 CDK4/6,如果 C21orf77 与细胞周期有关,则可能会降低其活性。

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
¥959.00
¥1489.00
¥3238.00
¥5585.00
¥42330.00
42
(0)

靶向表皮生长因子受体酪氨酸激酶,可能会抑制涉及 C21orf77 的下游信号通路。

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
¥1297.00
¥4682.00
11
(1)

抑制 BRAF V600E,可能会影响黑色素瘤细胞中包括 C21orf77 在内的信号通路。

Triciribine

35943-35-2sc-200661
sc-200661A
1 mg
5 mg
¥1151.00
¥1557.00
14
(1)

抑制AKT磷酸化与活化,可能抑制包括C21orf77在内的信号通路。

Simvastatin

79902-63-9sc-200829
sc-200829A
sc-200829B
sc-200829C
50 mg
250 mg
1 g
5 g
¥338.00
¥982.00
¥1489.00
¥4896.00
13
(1)

抑制 HMG-CoA 还原酶,可能会影响脂质筏和涉及 C21orf77 的相关信号通路。

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
¥699.00
¥1749.00
¥3610.00
233
(4)

抑制 mTOR,这可能会抑制涉及 C21orf77 的信号通路,影响其蛋白质相互作用或定位。

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
¥1230.00
¥3949.00
8
(0)

通过 E3 泛素连接酶复合物调节特定蛋白质的降解;如果 C21orf77 是该复合物的靶标,则可能包括 C21orf77。

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
¥2053.00
¥7818.00
88
(1)

抑制 ROCK 激酶,可能会影响细胞骨架组织和涉及 C21orf77 的信号通路。

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
¥440.00
¥1015.00
212
(2)

抑制 MEK,从而改变涉及 C21orf77 的 ERK 通路信号。

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
¥301.00
¥1128.00
257
(3)

抑制 JNK,如果 JNK 信号调节了 C21orf77 的活性,它可能会影响涉及 C21orf77 的信号通路。